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Systemic sclerosis is a fibrotic autoimmune disease in which aberrant remodeling of the extracellular 
matrix in organs disturbs their functionalities. The aim of this study was to investigate the expression of 
gelatinases on systemic sclerosis. Consequently, a mouse model of systemic sclerosis was employed and the 
gelatinolytic activity of gelatinases was evaluated on the fibrotic tissues of this model. 
Two groups of ten mice were considered in this work: a group of systemic sclerosis model and control 
group. For the generation of systemic sclerosis model, mice received bleomycin, while the control group was 
subjected to phosphate buffered saline (PBS) reception. Mice were tested for fibrosis by using trichrome 
staining, hydroxyproline measurement and α-SMA detection in tissue sections. Additionally, the gelatinolytic 
activity of matrix metalloproteinase 2 and matrix metalloproteinase 9 were measured using gelatin zymography 
in lungs and skin tissue homogenates.  
The obtained results indicated that subcutaneous injection of bleomycin-induced fibrosis in skin and lung 
tissues of mice. Pro and active forms of matrix methaloproteinase 9 were increased in fibrotic lung tissues 
(p<0.05 and p<0.01, respectively), while, the gelatinolytic activity of MMP2 was unaffected in these tissues. 
Additionally, in skin tissues of bleomycin-treated animals, both pro and active forms of MMP9 and MMP2 
were increased (p<0.05).  
Pro and active forms of gelatinases increase differently in skin and lung tissues of bleomycin-induced 
scleroderma. 
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INTRODUCTION 
 
Systemic sclerosis (SSc) is a fatal multisystem 
autoimmune disease in which tissue homeostasis is 
disrupted. Dysregulation of the immune system and 
production of auto antibodies cause vascular 
endothelial and alveolar epithelial cell injury; 
consequently, the fibrotic process is initiated in tissues. 
Cellular injury and aberrant healing lead to 
accumulation of extracellular matrix (ECM) proteins, 
especially collagen, in different organs.
1
 Excessive 
deposition of ECM results in tissue fibrosis which 
compromises tissue architecture and organ 
functions.
2
The amount of ECM proteins in tissues is 
controlled through the balance between their 




Matrix metalloproteinases are a family of 25 zinc-
dependent proteinases which are capable of degrading 
all extracellular matrix components. Most of MMPs are 
secreted as inactive zymogens and activated by 
proteolytic remodeling.
3
 At steady state, these proteins 
are not constitutively expressed; however, the 
exogenous stimuli such as various cytokines, growth 
factors, inflammation and cell to cell contact can 
induce their expression.
4,5
 Additionally, due to central 
roles of MMPs in morphogenesis, wound healing, 
tissue repair and remodeling, their activity is rigorously 
regulated.
6,7
 Dysregulation of MMP activities may lead 
to various pathological diseases such as inflammation, 
arthritis, cancer, and fibrosis.
8-10
 
MMP2 (gelatinase A) and MMP9 (gelatinase B), 
gelatinases, are the two well-known enzymes from 
MMPs family. It is generally accepted that MMP2 and 
MMP9 have considerable impacts on the degradation 
of fibrillar collagens after their initial cleavage by 
collagenases.
3,11 
Also Investigations demonstrate that 
these two gelatinases have direct collagenolytic 
activities and the ability to cleave several other ECM 
proteins such as elastin, type IV collagen, and latent 
TGF-β.
3
 Accordingly, gelatinases have an important 
function in ECM homeostasis and pathogenesis of 
fibrotic diseases. In an animal model of idiopathic 
pulmonary fibrosis (IPF) the activity of gelatinases 
increases in lung tissues. It is indicated that the type of 
gelatinases and their expressing cells are different in 
the early and late phase of disease episodes.
12,13
 These 
studies proposed that MMP2 and MMP9 are involved 
in the establishment of fibrosis in the early phase of 




Animal models are inevitable tools for 
understanding the pathogenesis of human disease. To 
the best of our knowledge, no study has investigated 
the alterations of gelatinases in tissues of an animal 
model of systemic sclerosis. Due to the immense 
impact of gelatinases in fibrotic disease, we induced a 
mouse model of systemic sclerosis with bleomycin 
(BLM) and evaluate the gelatinolytic activity of 
gelatinases in fibrotic murine tissues. Subcutaneous 
injection of bleomycin for 4 weeks described by 
Yamamoto et al, induces a mouse model of 
scleroderma.
14
In this model, skin fibrosis is 
accompanied by lung fibrosis, inflammation, and 





MATERIALS AND METHODS 
 
Animal Model of Systemic Sclerosis 
In order to investigate the activity of gelatinases in 
systemic sclerosis (SSc), an animal model of disease 
was employed. Six to eight weeks old female BALB/c 
mice were acquired from Pasteur Institute (Tehran, 
Iran) and were kept at the Center of Experimental and 
Comparative Studies (Tehran, Iran). The mice were 
kept in the standard laboratory cages at room 
temperature and ambient humidity under a 12-hour 
reverse light-dark cycles. They received ad libitum 
access to the normal laboratory chow and water. Prior 
to the beginning of the experiments, the mice were 
retained in the laboratory cages for a period of two 
weeks in order to acclimate to the laboratory 
conditions. Then, they were randomly divided into two 
groups of 10 mice termed as Bleomycin (BLM) and 
control (Phosphate buffered saline (PBS)) groups. SSc 
was induced in mice according to protocol suggested 
by Yamamoto et al.
14
 Briefly, each mouse in BLM 
group received daily 0.15 unites of bleomycin which 
was dissolved in 100 µL PBS. Bleomycin (Nippon 
Kayaku, Tokyo, Japan) was injected subcutaneously 
into the shaved back skins of mice daily for a period of 
28 days. In this approach control mice (PBS) received 
100 µL PBS subcutaneously for 28 days. It should be 
noted that all of the conducted animal experiments in 
the current research are approved by the Animal Care 
Committee of Iran University of Medical Sciences  
(N.: IR.IUMS.FMD.REC1394.25723). 
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Tissue Harvesting, Histology, and 
Immunohistochemistry 
On day 29 under deep anesthesia, the chest was 
opened and lungs were removed. The skin in 
bleomycin or PBS injection site was excised. The left 
lungs and half of the excised injured skins were fixed 
overnight in 10% neutral formalin. Paraffin-embedded 
4 μm tissue sections from lung and skin were stained 
with Hematoxylin-eosin and Masson’s trichrome.  
In microscopic examination, fibrosis was detected 
by the tissue content of collagen which was stained 
blue by trichrome staining. The dermis thickness was 
defined as the distance between the epidermal-dermal 
junction and the dermal-subcutaneous fat junction.
15
 
After image acquisition from trichrome sections under 
the light microscope at 100X magnification, the 
thickness was measured by ImageJ software (Fiji- 
Win64) in 5 different skin field of each specimen.
15
 
Tissue microscopic evaluations were performed by two 
independent observers. 
The appearance of myofibroblasts is an essential 
step in tissue repair and fibrosis formation process. 
Alpha-smooth muscle actin (α-SMA) is a useful marker 
for the identification of myofibroblasts. For detection 
of α –SMA, 5μm sections from injured skin and lung 
were deparaffinized and rehydrated. After the antigen 
was retrieved with fresh sodium citrate buffer, sections 
were blocked with H2O2 and bovine serum albumin. 
Slides were incubated with conjugated primary 
antibody α-SMA-HRP (1:500, Santa Cruz 
Biotechnology, USA) overnight at 4˚C. The chromogen 
diaminobenzidine tetra hydrochloride (DAB, Sigma-
Aldrich, St. Louis, MO, USA) was added until 
sufficient color developed. Finally, sections were 
counterstained with hematoxylin. For quantification, α- 
SMA positive cells were counted in all microscopic 
fields of skin tissue sections. In lung tissues, percent of 
α- SMA positive areas were calculated by imageJ 
software in images of 10 random microscopic fields, 
then the mean percent of α-SMA positive areas was 
determined for each specimen.  
 
Hydroxyproline Assay  
Collagen deposition was estimated as a marker for 
fibrosis by hydroxyproline measurement. After tissue 
excision, two upper lobes from right lungs and the one-
fourth of the excised skins were immediately snap 
frozen and stored at -80˚C until the process of 
hydroxyproline assay. Hydroxyproline was measured 
with hydroxyproline assay kit (Sigma Aldrich, St. 
Louis, MO, USA) according to manufacturer protocol. 
 
Gelatin Zymography 
Gelatin zymography was performed according to 
the Toth and Fridman protocol to detect semi 
quantitatively pro and active levels of MMP2 and 
MMP9.
16 
MMP2 and MMP9, due to their gelatinolytic 
activity, hydrolysegelatin, that was embedded in the 
polyacrylamide gel in the gelatin zymographic method. 
After coomassie staining, areas of degradation are 
visible as clear bands against a darkly blue stained 
background. 
For gelatin zymography, lower lobes of right lungs 
and other one-fourth of excised skins were 
homogenized in ice-cold homogenization buffer  
(25 mM Tris–HCl PH 7.5, 100 mM NaCl, 1% Triton X 
-100 and Protease inhibitor) and centrifuged at 
10,000×g for 10 min at +4°C. The supernatants were 
stored at −40°C until further analysis. 
Total protein concentrations were measured with 
the bicinchoninic acid assay (Pars Tous, Iran). For each 
sample, 20 μg of total protein was mixed with non-
reducing sample buffer and electrophoretically 
(constant voltage125) separated in SDS polyacrylamide 
(10%) gel containing 1 mg/ml gelatin. Gels were then 
treated with 2.5% Triton X-100 for 45 min at room 
temperature to remove SDS. Zymograms were 
subsequently incubated 16 hours at 37 °C in developing 
buffer (50 mM Tris-HCl, pH 7.8, 0.2 M NaCl, 5 mM 
CaCl2, and 0.02% v/v Triton –X 100). The gels were 
stained with 0.5% Coomassie Blue R-250 and 
destained in 10% acetic acid and 30% ethanol in dH2O. 
Human recombinant MMP9 (R&D) protein was used 
as positive control. Prestained protein marker 
(SMOBIO 9-245 kDa) was used as molecular weight 
standard. For densitometric analysis of bands,imageJ 
software was used. 
 
Statistics  
Statistical analysis was performed using Graph Pad 
Prism (version 8). Unpaired t-test was used for data 
analysis. All data are expressed as mean±SEM. 
Differences were considered significant when 
probability value (p)<0.05 (denoted as *), p<0.01 
(denoted as **), p<0.001 (denoted as ***) and 
p<0.0001 (denoted as ****). 
 
 
Gelatinases Increase in Bleomycin-induced Systemic Sclerosis Mouse Model 
185/ Iran J Allergy Asthma Immunol                                                Vol. 18, No. 2, April 2019 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
RESULTS 
 
Bleomycin-induces Fibrosis in Skin and Lung 
Tissues of Mice 
Bleomycin injection caused fibrosis in skin and 
lung tissues of mice as we described in our previous 
work.
15 
Fibrosis was accompanied with an increase in 
dermis thickness and hydroxyproline amount in skin 
and lung tissues of mice.
15
 
Bleomycin injection enhanced the expression of α-
SMA in skin and lung tissues of mice compared with 
control group (p<0.05 in the skin and p<0.001 in the 




Figure 1. Bleomycin increases the expression of α-SMA in skin and lung tissues of bleomycin-induced systemic sclerosis 
mouse model. (A) Immunohistochemistry staining of α-SMA in skin and lung tissues of control group and bleomycin-induced 
systemic sclerosis mouse model group. Original magnification was 100X for skin (top) and 200X for lung slides (below). (B) 
Quantitative expression of α-SMA in skin tissues of control group and bleomycin-induced systemic sclerosis mouse model 
group. (C) Quantitative expression of α-SMA in lung tissues of control group and bleomycin-induced systemic sclerosis 
mouse model group. Results are presented as Mean±SEM. N=9-10 mice in each group. Data was analysed with unpaired 
 t-test. BLM=Bleomycin group, PBS=Control group, α-SMA=Alpha-smooth muscle actin, p=probability value, ***=p<0.001, 
*=p<0.05 
 
MMP9 Increases in Bleomycin-induced Lung 
Fibrosis  
Zymographic analysis from lung tissue lysates of 
control group showed little or no bands of pro MMP9 
and pro MMP2. Bleomycin administration significantly 
induced the expression of MMP9 bands in zymograms 
(Figure 2A).Administration of bleomycin increased the 
expression of active and pro MMP2 in a non-significant 
manner (p>0.05) (Figure 2B). The mean expression of 
active MMP9 in the bleomycin-treated group was 2.9 
fold higher than the control group (26503±5658 vs 
9121±1850, p<0.01) (Figure 2C). Additionally, the 
expression of pro MMP9 in BLM group was 
significantly higher than the control group 
(16660±5405 vs 4476±1058, p<0.05) (Figure 2C). 
 
MMP9 and MMP2 Increase in Bleomycin-induced 
Skin Fibrosis  
Analysis of gelatin zymographic gels demonstrated 
that MMP2 was the main gelatinase in skin tissues. In 
most normal skin lysates, MMP9 did not show any 
activity (Figure 3A). Bleomycin-induced-fibrosis 
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augmented gelatinase activity in zymograms (Figure 
3A). Expression of pro and active forms of MMP2 in 
skin zymograms of bleomycin received mice was 
intensified compared with control group (respectively 
4411±758.8 vs 1813±192.0, 3213±488.2 vs 
1632±224.5, p<0.05) (Figure 3B). Pro and active 
MMP9 increased in skin tissues of bleomycin received 
mice compared with the control group (respectively 
29043±9779 vs 6044±1813, 18438±6016 vs 





Figure 2. MMP9 increases in lung tissues of bleomycin-induced systemic sclerosis mouse model. (A) Gelatin zymography of 
lung tissue lysate. 92 KDa=Pro MMP9, 88 KDa=Active MMP9, 72 KDa=Pro MMP2, 68 KDa=Active MMP2. (B) Density 
values of MMP9 in lung tissues. (C) Density values of MMP2 in lung tissues. Results are presented as Mean±SEM. N=9-10 
mice in each group. Data was analysed with unpaired t-test. BLM=Bleomycin group, PBS=Control group, p=probability 





Figure 3. Gelatinases increase in skin tissues of bleomycin-induced systemic sclerosis mouse model. (A) Gelatin zymography 
of skin tissue lysate. 92 KDa=Pro MMP9, 88 KDa=Active MMP9, 72 KDa=Pro MMP2, 68 KDa=Active MMP2. (B) Density 
values of MMP9 in skin tissues. (C) Density values of MMP2 in skin tissues. Results are presented as Mean±SEM. N=9-10 





The obtained experimental results demonstrate that 
gelatinases increase in the lungs and skin tissues of a 
mouse model of systemic sclerosis. 
Systemic sclerosis (SSC) is a multisystem fibrotic 
autoimmune disease. Cell injury and aberrantly 
sustained production of cytokines, growth factors, and 
A 
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angiogenic factors in SSc result in a deregulated tissue 
repair. These deregulated repairs in a tissue tilt its 
homeostasis toward hyperplasia and excessive 
accumulation of extracellular matrix (ECM).
1
 
Excessive deposition of ECM components in tissues  
of an organ leads to fibrosis which destroys the 
operations of the organ.
1
 Due to the importance of 
ECM in the maintenance of organ function, regulation 
of its homeostasis is strictly critical. Studies emphasize 
that MMPs and their endogenous inhibitors represent  
a fundamental effect in this maintenance and their 
alterations can play a crucial role in the pathogenesis  
of fibrotic diseases.
2
Additionally, MMPs have a 
significant task in immunity and repair particularly in 
the procedures like cell migration, leukocyte activation, 
antimicrobial defense, and chemokine processing.
17
 As 
stated previously, the general function of MMPs is the 
degradation of the ECM proteins. It is argued that this 
functionality diminishes in fibrotic organs; however, 
considering the other operations of MMPs, this notion 
may be inaccurate.
18
 Accordingly, animal models and 
in vitro studies indicate pro and anti-fibrotic effects for 
MMPs. MMP3 and MMP7 in the mouse model of 
idiopathic pulmonary fibrosis (IPF) show pro-fibrotic 
function. Overproduction of MMP3 leads to fibrosis,  
as a result, bleomycin-induced fibrosis was 




Over expression of MMP2 and MMP9 was 
confirmed in IPF patients, their expressions were seen 
in myofibroblasts, neutrophils, and epithelial cells.
21,22 
Also, alveolar macrophages of these patients expressed 
excessive amounts of MMP9 which was reduced by 
immunosuppressive therapy.
23
 The increment of 
gelatinases causes the disruption of the basement 
membrane and the invasion of fibroblast to the alveolar 
spaces which in turn benefits the fibrotic process.
21,22
 In 
SSc patients with interstitial lung disease (SSc- ILD) 
amount and activity of MMP9 is increased in 
bronchoalveolar lavages compared with 
bronchoalveolar lavages of SSc patients without ILD 
and healthy controls.
24
 Even though, there are no data 
available concerning the expression of these two 
gelatinases in tissues of SSc-ILD patients. Our results 
showed overexpression of pro and active form of 
MMP9 in fibrotic lung tissue and these are in 
accordance to results obtained from bronchoalveolar 
lavages of SSc-ILD patients and also compatible with 
results obtained from IPF patients. 
In bleomycin-induced IPF, the expression of MMP9 
is elevated especially in the early phase of disease 
induction. In this phase, MMP9 contributes to 
disruption of the alveolar epithelial cell basement 
membrane and progression of fibrosis. In the late 
stages, the gelatinolytic activities of the latent and 
active forms of MMP2 are prominent, and MMP2 is 
localized to the regenerated alveolar epithelial cells. 
MMP2, especially its active form, possibly plays a role 
in alveolar epithelial cell regeneration.
12,13
 In our study 
MMP9 was elevated but the increment of MMP2 was 
not seen, this event may be due to the use of different 
delivery protocols of bleomycin. In IPF model direct 
instillation of bleomycin occurred one time through 
trachea but in subcutaneous injection delivery of 
bleomycin occurs for 28 days period.
25
 In our model, 
chronic injury exists and repair does not occur until the 
injection is stopped, therefore increment of MMP2 for 
repairing was not seen in this model. Necessarily, 
further investigation would be done to evaluate the 
gelatinase activity after the induction of fibrosis and 
with the initiation of repair in a mouse model of 
scleroderma. 
Despite the assumed function of MMP9 in lung 
fibrosis, the MMP9 null mice developed fibrosis 
similar to that of wild-type after bleomycin 
administration.
26
 By contrast, over expression of 
MMP9 in transgenic mice decreased bleomycin-
induced fibrosis.
27 
The discrepancy between the results 
reported by different groups can be partly due to the 
timing of pathological assessment. Fibrosis process 
initiates with injury, inflammation, repair and finally 
resolution, the latter being was disrupted in the fibrotic 
disease. It is assumed that if MMPs are expressed in the 
early phase of disease induction, they have a pro-
fibrotic effect but in late stages, they have an anti-
fibrotic effect.
18
 Our study was done in the late stage of 
disease, therefore overexpression of MMP9 in fibrotic 
lung tissues may have an anti-fibrotic and protective 
effect against the bleomycin-induced fibrosis.  
MMP2 is expressed constitutively by several types 
of skin cells, but the expression of MMP9 is restricted 
in normal skin tissues.
28
 Myofibroblasts from SSc 
patients and healthy controls do not express MMP9 but 
the activity of MMP2 is enhanced in SSc fibroblasts.
29
 
The serum level of MMP2 in scleroderma patients is 
not different from normal controls, while the serum 
level of MMP9 is elevated in SSc patients. Skin scores 
in SSc patients are positively correlated with the serum 
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level of MMP9.
30,31
 In contrast to lung tissue (IPF 
patient), the expression of MMP9 in the skin of diffuse 
cutaneous SSc patients are low, but this expression 
does not alter in limited cutaneous disease.
32
 In keeping 
with results of other studies, our results indicate that in 
all samples of control skin, the gelatinolytic activity of 
MMP2 exists but the amount of MMP9 is low in 
normal skin tissues. We detected the increment of 
MMP2 in fibrotic skins but our obtained MMP9 data 
was different from results achieved from SSc patients, 
this may be due to the different origin of samples. 
However, it is obscure whether the overexpression of 
MMPs is a defense reaction of the body against the 
fibrogenic effect of bleomycin or this overproduction 
has synergy with the fibrogenic effect of bleomycin. 
There is still much unknown concerning the action of 
gelatinases in SSc based on the complexity in their 
functions, regulation and the lack of animal studies. 
Therefore further animal studies are required.  
In this study, we could not evaluate the activity of 
gelatinases and their inhibitors (TIMPs) in fibrotic 
tissues before and after the disease induction. Also, it is 
necessary to mention that gelatinase zymography is a 
semiquantitative method therefore further techniques 




In conclusion, according to other studies, our study 
shows that MMPs activity is different and specific in 
various organs. The major gelatinase in normal lung 
tissue is MMP-9 while in skin tissue the MMP2 is 
highly expressed. In fibrotic lung and skin tissues, 
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